AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
Crude futures headed higher on Thursday, with prices on track to tally their first gain in five sessions, supported in part by an unexpected decline in last week’s U.S. crude inventories, which followed sizeable back-to-back weekly gains.
Business inventories rose 0.3% for the second straight month and for the fifth straight month overall in August, the Commerce Department said Thursday.
More than 165 jobs to go as company seeks to extend cash runway and focus on postpartum drug launch.
Builder sentiment inched up in October, the National Association of Home Builders said.
By the year 2047, the global population will have more people in retirement age than young people.